BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31462556)

  • 21. Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas.
    Hrasćan R; Pećina-Slaus N; Martić TN; Colić JF; Gall-Troselj K; Pavelić K; Karapandza N
    J Neuroendocrinol; 2008 Aug; 20(8):1015-22. PubMed ID: 18510707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor.
    Quevedo R; Spreafico A; Bruce J; Danesh A; El Ghamrasni S; Giesler A; Hanna Y; Have C; Li T; Yang SYC; Zhang T; Asa SL; Haibe-Kains B; Krzyzanowska M; Smith AC; Singh S; Siu LL; Pugh TJ
    Genome Med; 2020 Apr; 12(1):38. PubMed ID: 32345369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
    VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
    Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
    Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
    Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
    Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
    Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
    Heaphy CM; Singhi AD
    Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
    Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
    Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
    Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
    Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
    Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
    de Wilde RF; Edil BH; Hruban RH; Maitra A
    Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic insulinoma: exploration from clinicopathological signatures and genetic characteristics.
    Zhang J; Jiang R; Hong X; Wu H; Han X; Wu W
    Front Oncol; 2023; 13():1109330. PubMed ID: 37251916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
    Singhi AD; Klimstra DS
    Histopathology; 2018 Jan; 72(1):168-177. PubMed ID: 29239037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypo-methylation mediates chromosomal instability in pancreatic NET.
    Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
    Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
    Pipinikas CP; Berner AM; Sposito T; Thirlwell C
    Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data.
    Kit OI; Trifanov VS; Petrusenko NA; Gvaldin DY; Kutilin DS; Timoshkina NN
    Mol Biol Rep; 2020 Jun; 47(6):4233-4243. PubMed ID: 32451928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggressive versus indolent insulinomas: new clinicopathological insights.
    Hackeng WM; Brosens LAA; Dreijerink KMA
    Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36779771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical and in situ hybridization analyses of glucose transporter 2 in pancreatic neuroendocrine tumors: Possible glucose transporter 2 association with neoplastic insulin production.
    Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
    Pathol Res Pract; 2024 Jan; 253():154966. PubMed ID: 38043192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas.
    Lichtenauer UD; Di Dalmazi G; Slater EP; Wieland T; Kuebart A; Schmittfull A; Schwarzmayr T; Diener S; Wiese D; Thasler WE; Reincke M; Meitinger T; Schott M; Fassnacht M; Bartsch DK; Strom TM; Beuschlein F
    J Clin Endocrinol Metab; 2015 May; 100(5):E776-82. PubMed ID: 25763608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.